Department of Microbiology and Immunology, Room A-5301, Medical Center North, 1161 21st Ave. S., Vanderbilt University School of Medicine, Nashville, TN 37232-2363, USA.
Exp Neurol. 2011 Jan;227(1):19-23. doi: 10.1016/j.expneurol.2010.10.009. Epub 2010 Oct 20.
Glatiramer acetate (GA, copolymer-1, Copaxone) is a Food and Drug Administration-approved drug for the treatment of relapsing-remitting multiple sclerosis (MS). However, its mechanism of action remains ill-defined. The available evidence indicates that GA induces antigen-presenting cells with anti-inflammatory properties and promotes the generation of immunoregulatory T cells that suppress pathogenic T cells. A new study by Kala et al. (2010) now shows that B lymphocytes, which are best known for their antibody-secreting properties, contribute to the beneficial effects of GA against experimental autoimmune encephalomyelitis (EAE), the animal model of MS. This commentary discusses these new findings in the context of the pathogenesis of MS and EAE, the emerging immunoregulatory role of B cells in autoimmunity, and the relevance of B cells as targets for immunotherapy in MS.
醋酸格拉替雷（GA，共聚物-1，Copaxone）是一种经美国食品药品监督管理局批准用于治疗复发缓解型多发性硬化症（MS）的药物。然而，其作用机制仍不清楚。现有证据表明，GA 诱导具有抗炎特性的抗原呈递细胞，并促进产生免疫调节性 T 细胞，抑制致病性 T 细胞。Kala 等人的一项新研究（2010）表明，B 淋巴细胞，其以分泌抗体的特性而闻名，有助于 GA 对实验性自身免疫性脑脊髓炎（EAE）的有益作用，EAE 是 MS 的动物模型。该评论讨论了这些新发现与 MS 和 EAE 的发病机制、B 细胞在自身免疫中的新兴免疫调节作用以及 B 细胞作为 MS 免疫治疗靶点的相关性。
